VoxelLTS:0QDB 97 Return-on-Tangible-Equity is 43.35% as of Mar. 2026, which is 32% above its 10-year median of 32.81. GuruFocus rates LTS:0QDB with a GF Score™ of 97/100 and a GF Value™ of zł128.03. The stock has 2 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Voxel ranks better than 79.79% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Voxel's annualized net income for the quarter that ended in Mar. 2026 was zł127.6 Mil. Voxel's average shareholder tangible equity for the quarter that ended in Mar. 2026 was zł294.4 Mil. Therefore, Voxel's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 43.35%.
The historical rank and industry rank for Voxel's Return-on-Tangible-Equity or its related term are showing as below:
LTS:0QDB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 16.55 Med: 32.81 Max: 55.31
Current: 38
During the past 13 years, Voxel's highest Return-on-Tangible-Equity was 55.31%. The lowest was 16.55%. And the median was 32.81%.
LTS:0QDB's Return-on-Tangible-Equity is ranked better than 79.79% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs LTS:0QDB: 38.00
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Voxel Return-on-Tangible-Equity Related Terms
Voxel Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Voxel's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QDB vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Voxel's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voxel Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Voxel's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Voxel's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 43.35% mean?
Voxel (LTS:0QDB) has a Return-on-Tangible-Equity of 43.35% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Voxel and its competitors. This is 32% above median its historical median of 32.81. Over the past decade, Voxel's Return-on-Tangible-Equity has ranged from 16.55 to 55.31. According to the industry distribution chart, Voxel ranks #39 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 20.2%.
Is Voxel's Return-on-Tangible-Equity too high?
Voxel's current Return-on-Tangible-Equity of 43.35% is 32% above median its 10-year median of 32.81. Over the past 10 years, this metric has ranged from a low of 16.55 to a high of 55.31. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.07. Voxel's value of 43.35% is 61828.6% above this industry median. Based on the distribution chart, Voxel ranks #39 out of 193 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Voxel has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Voxel's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Voxel ranks #39 out of 193 companies for Return-on-Tangible-Equity. This places Voxel in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 0.07. Voxel's value of 43.35% is 61828.6% above this benchmark. Historically, Voxel's own Return-on-Tangible-Equity has ranged from 16.55 to 55.31 over the past decade. While the company's 10-year median is 32.81 vs. the industry median of 0.07, Voxel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voxel's current Return-on-Tangible-Equity of 43.35% is 61828.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Voxel and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voxel's current Return-on-Tangible-Equity is 43.35%, which is 32% above median its own 10-year median of 32.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voxel stock overvalued right now?
Voxel (LTS:0QDB) has a current Return-on-Tangible-Equity of 43.35%. The stock's GF Value™ is zł128.03, compared to a current price of zł109.00 — trading 14.9% below its estimated fair value. The current Return-on-Tangible-Equity is 43.35%, which is 32% above median its 10-year median of 32.81 and 61828.6% above the Medical Diagnostics & Research industry median of 0.07. Voxel's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Voxel (LTS:0QDB), the current Return-on-Tangible-Equity is 43.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voxel (LTS:0QDB) Overvalued in 2026?
Based on GuruFocus' analysis, Voxel stock appears to be undervalued.
The current stock price of zł109.00 is trading 14.9% below its estimated GF Value™ of zł128.03.
Key valuation signals for LTS:0QDB:
Return-on-Tangible-Equity: 43.35% (32% above median its 10-year median of 32.81)
GF Value™: zł128.03 vs. price of zł109.00 (14.9% below fair value)
Industry Position: 61828.6% above the Medical Diagnostics & Research median (#39 of 193)
No single metric tells the full story. See the LTS:0QDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voxel SA is a network of diagnostic imaging laboratories created for patients and to increase access to high-quality tests. The company operates diagnostic imaging centers and laboratories and provides several services such as magnetic resonance imaging, computed tomography and positron emission tomography. It has 33 specialised laboratories in 21 cities throughout Poland.
97GF Score
Get the complete analysis for LTS:0QDB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QDB has been successfully added to your 
